Eugene Milshteyn1, Harry Griffin2, Yi Shuen Chang2, Tim Sprenger3,4, Stefan Skare4,5, Christopher J. Maclellan2, and Salil Soman2
1GE Healthcare, Boston, MA, United States, 2Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States, 3GE Healthcare, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Sweden, 5Karolinska University Hospital, Stockholm, Sweden
Synopsis
Keywords: Multi-Contrast, Brain
The focus of this study is to assess the diagnostic
performance of NeuroMix, a single push-button, novel, fast multi-contrast MRI
sequence, to that of routine brain scans that typically consist of multiple
sequences. NeuroMix has the ability to provide several different contrasts in
about 3.5 minutes with only one prescription and prescan. While the sequence
has initially shown to be fast and motion-robust, more evaluation is needed
across the various contrasts compared to gold standard, optimized sequences
routinely used in the clinic. Here we present initial qualitative and
quantitative comparisons between NeuroMix and routine scans across a variety of
patients.
Introduction
Recent developments in fast, multi-contrast MRI sequences have
provided new opportunities in rapid neurological scanning1-3. For
routine scanning, these sequences provide the necessary image contrasts for
proper diagnosis in a short total scan time. One such recent development is
NeuroMix (NM), which can provide T1-FLAIR/T2-FLAIR/T2*w/T2w/T1w/SWI/DWI/ADC
images in ~3.5 minutes with full brain coverage1. NeuroMix is an
enhancement of the EPI based EPIMix2, with inclusion of SSFSE for
better T2 contrast, and additional contrasts1. However, there is
still a need to evaluate NM in the clinical setting as has recently been done
with EPIMix4-6. The goal of this study was to compare the qualitative
and quantitative diagnostic performance of NM relative to routine clinical
brain MRI protocols.Methods
All exams were performed on a 3T Premier MR system (GE
Healthcare, WI, USA). NM was included within routine brain protocols at Beth
Israel Deaconess Hospital, which generally consisted of routine T1-FLAIR/T2-FLAIR/T2*w/T2w/DWI
(and sometimes MPRAGE) sequences. For routine sequences, where possible, a
commercial deep learning (DL) reconstruction was applied (AIR™ Recon DL, GE
Healthcare)7. Figure 1 presents the acquisition parameters of NM versus
the Routine Protocols. 39 patients clinically indicated for brain MRI were scanned
between April 2022-September 2022, and retrospectively included in this study
under an IRB approved protocol. The retrospective data was gathered without
sub-grouping into different disease types (some example findings listed in Figure 1).
NM imaging was performed prior to any contrast administration for all but 2
cases.
Qualitative Assessment: 3 Readers (1 CAQ certified Neuroradiologist
and 2 diagnostic radiology residents) were asked to assess the diagnostic
confidence of Neuromix by comparison of image quality metrics to the routine
MRI, which was considered the gold standard (see Figure 2). Each reader
reviewed both the NM and routine precontrast images for visibility of the
pathology (if present) on the exam, and scored them as equivalent, or required routine
MRI to make diagnosis. Each of the relevant contrasts in each group (Neuromix
and Routine) were rated on basis of three criteria after reviewing the NM and routine
images:
1. Would the reader be comfortable replacing a
noncontrast routine MRI Brain protocol with the set of NM images.
2. Would the reader be comfortable replacing a
noncontrast routine MRI Brain sequence with the corresponding NM sequence. If
yes, which ones.
3. Would the reader be comfortable reading a
noncontrast NM sequence if the corresponding routine MRI Brain sequence was not
available. If yes, which ones.
4. Is the major pathology from the study
equivalently visible on NM and routine non contrast images.
Rating agreement was calculated using Fleiss’ Kappa.
Quantitative Assessment: The signal-to-noise ratio
(SNR) and contrast-to-noise ratio (CNR) for the core NeuroMix contrasts was
calculated according to the equations used in Magnotta et al.8 The
CSF, white matter (WM), and gray matter (GM) were segmented on the T2w images
via FSL FAST9 and applied to other contrasts. For DWI, the
coefficient of variation (CV) in the apparent diffusion coefficient (ADC) map
was calculated in a representative axial slice for both NeuroMix and routine
protocols and compared via a t-test. Results
Qualitative: For question 1, all readers responded
no. For question 2, all readers responded yes regarding substituting any of the
NM sequences in place of the corresponding routine sequence. Regarding which
sequence they would be comfortable substituting, all responded yes for DWI, all
responded no for FLAIR, 3D T1 EPI, or T2*. There was limited agreement with
regard to T1 (Kappa -0.5), T2 (Kappa -0.4), SS T2 (Kappa -.03) and SWI (Kappa
-.02). See Figure 3 for some artifacts routinely encountered in NM sequences,
and Figure 4 for examples where NM provided better images relative to routine
MRI.
For question 3, all 3 readers overall responded yes they
would prefer reading some NM sequences if the alternative was to not have the
corresponding routine sequences, with the exception of 1 reader for 2 cases (Kappa
-.02). To which of the specific NM sequences for Q3, all readers responded yes
for DWI/T2SSFSE/SWI. There was limited agreement regarding T1 (Kappa -0.09), T2,
FLAIR (Kappa -0.2), 3D T1 (Kappa -0.1), and T2* (Kappa -0.09).
For question 4, all readers responded yes, the pathology
visualized on the noncontrast brain images was visible in the corresponding NM
series but 1 case.
Quantitative: Figure 5 shows the calculated SNR and
CNR for multiple NeuroMix contrasts. In all cases, the SNR and CNR was high
enough to visualize the relevant anatomy. Furthermore, in the cases of FLAIR
acquisitions, the GM and WM SNR was considerably higher than the CSF,
indicating good nulling of the CSF. Additionally, there was no statistically
significant difference between the CV in the Neuromix and routine ADC maps (p =
0.084). Discussion
Qualitative analysis revealed both positives and some
pitfalls of NeuroMix, while the quantitative analysis showed high enough SNR
and CNR. These results indicate Neuromix as having the capability to be a
backup sequence in case artifacts are present in routine sequences, or potentially
a replacement for some contrasts altogether. These encouraging results warrant
a continuation of the study, including increasing the cohort size and calculating
SNR/CNR across the whole brain volume.Acknowledgements
No acknowledgement found.References
1. Sprenger et al. NeuroMix—A single-scan brain exam. Magn
Reson Med. 2022:87:2178-2193.
2. Skare et al. “A 1-minute full brain MR exam using a
multicontrast EPI sequence,” Magn Reson Med. 2018;79:3045-3054.
3. Clifford et al. “An artificial intelligence-accelerated
2-minute multi-shot echo planar imaging protocol for comprehensive high-quality
clinical brain imaging,” Magn Reson Med. 2022;87:2453–2463.
4. Delgado et al. “Diagnostic performance of a new multicontrast
one-minute full brain exam (EPIMix) in neuroradiology: A prospective study,” J
Magn Reson Imaging 2019;50:1824-1833.
5. Ryu et al. “Clinical experience of 1-minute brain MRI
using a multicontrast EPI sequence in a different scan environment,” Am J
Neuroradiol 2020;41:424-429.
6. Kits et al. “One-minute multi-contrast Echo planar brain
MRI in ischemic stroke: A retrospective observational study of diagnostic
performance,” J Magn Reson Imaging 2021;54:1088-1095.
7. Lebel, RM. “Performance
characterization of a novel deep learning-based MR
image reconstruction pipeline,” arXiv
2020.
8. Magnotta et al. “Measurement of Signal-to-Noise and
Contrast-to-Noise in the fBIRN Multicenter Imaging Study,” J. Digit Imaging
2006;19:140-147.
9. Zhang et al. “Segmentation of brain MR images through a
hidden Markov random field model and the expectation-maximization algorithm,” IEEE
Trans Med Imag 2001;20(1):45-57.